DXCM : Insider Transactions for DexCom Inc | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

DexCom Inc (DXCM)

$110.57

6.07 (5.2%) as of 4:30 Mon 6/24

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

389,580,000

Market Cap:

43.08(B)

Last Volume:

4,690,332

Avg Vol:

1,930,532

52 Week Range:

$75.49 - $140.45

Level I Sector:

Health Care

Level II Sector:

Health Services

Level III Sector:

Medical Instruments & Supplies

Member Indexes:

NASDAQ COMPOSITE

NASDAQ NNM COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 487

Guru Rank Value : 3

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	71,005	274,979	309,595	581,627
Total Sell Value	$9,585,020	$36,298,507	$40,264,880	$70,726,419
Total People Sold	8	10	14	16
Total Sell Transactions	13	27	50	85
End Date	2024-03-24	2023-12-22	2023-06-23	2022-06-23

Adjust Filter Settings

Records found: 2309

Page 36 of 93

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

EVP, Clinical and Regulatory

• – –

2017-05-10

4

AS

$71.93

$230,176

D/D

(3,200)

109,633

-

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-04-24

4

AS

$75.89

$110,041

D/D

(1,450)

117,424

-

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-04-24

4

AS

$75.78

$241,131

I/I

(3,182)

6,369

-

Gregg Terrance H

Executive Chairman

• • –

2017-04-20

4

S

$74.10

$1,111,500

I/I

(15,000)

40,882

-

President & CEO

• • –

2017-04-17

4

AS

$75.63

$756,317

D/D

(10,000)

343,680

-

President & CEO

• • –

2017-04-17

4

OE

$8.79

$87,900

D/D

10,000

353,680

-

EVP, Clinical and Regulatory

• – –

2017-04-10

4

AS

$78.19

$250,208

D/D

(3,200)

112,833

-

Interim CFOOfficer

• – –

2017-04-01

3

IO

$0.00

$0

D/D

0

26,683

-

Pacelli Steven Robert

EVP, Strategy & Corp. Dev.

• – –

2017-03-23

4

AS

$76.25

$304,006

D/D

(3,987)

118,874

-

Doubleday Richard

EVP, Chief Commercial Officer

• – –

2017-03-23

4

AS

$76.38

$243,029

I/I

(3,182)

9,551

-

SVP, CFO

• – –

2017-03-22

4

AS

$75.97

$151,937

I/I

(2,000)

8,452

-

President & CEO

• • –

2017-03-17

4

AS

$77.82

$778,158

D/D

(10,000)

343,680

-

President & CEO

• • –

2017-03-17

4

OE

$8.79

$87,900

D/D

10,000

353,680

-

Director

– • –

2017-03-14

4

S

$77.36

$232,080

I/I

(3,000)

21,304

-

Leach Jacob Steven

SVP, Research & Development

• – –

2017-03-14

4

S

$77.32

$235,824

D/D

(3,050)

82,155

-

Leach Jacob Steven

SVP, Research & Development

• – –

2017-03-13

4

S

$77.78

$617,991

D/D

(7,926)

85,205

-

CTO

• – –

2017-03-13

4

AS

$77.74

$1,119,514

I/I

(14,400)

10,442

-

Leach Jacob Steven

SVP, Research & Development

• – –

2017-03-10

4

OE

$7.63

$57,225

D/D

7,500

93,131

-

Leach Jacob Steven

SVP, Research & Development

• – –

2017-03-10

4

D

$77.55

$772,482

D/D

(9,961)

85,631

-

SVP, CFO

• – –

2017-03-10

4

D

$77.55

$744,951

D/D

(9,606)

46,497

-

CTO

• – –

2017-03-10

4

D

$77.55

$826,534

I/I

(10,658)

24,842

-

CTO

• – –

2017-03-10

4

A

$78.24

$2,503,758

I/I

32,001

35,500

-

CTO

• – –

2017-03-10

4

D

$77.55

$485,001

D/D

(6,254)

34,079

-

CTO

• – –

2017-03-10

4

AS

$78.24

$2,503,758

D/D

(32,001)

40,333

-

SVP, Operations

• – –

2017-03-10

4

D

$77.55

$922,309

I/I

(11,893)

64,664

-

2309 Records found	Previous 30 31 32 33 34 35 36 37 38 39 Next	Page 36 of 93

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.